Nature子刊:神经酰胺连接饮食与心血管代谢疾病
创作:阿当 审核:Bingbing 03月19日
  • 对EPIC波茨坦研究进行巢式病例对照研究,2型糖尿病(T2D)775人、心血管疾病(CVD)551人、随机亚列队1137人;
  • 神经酰胺C18:0和C22:0及二氢神经酰胺C20:0和C22:2与T2D风险正相关,神经酰胺C20:0及二氢神经酰胺C26:1相反;
  • 神经酰胺C16:0和二氢神经酰胺C22:2,与CVD风险正相关;
  • 全基因组关联分析和孟德尔随机分析显示神经酰胺C22:0在T2D病因中起作用;
  • (二氢)神经酰胺部分介导了高红肉摄入带来的可能不良影响和咖啡对T2D风险的益处。
主编推荐语
Bingbing
心血管代谢疾病发生之前往往伴随着代谢的改变。本文就神经酰胺和二氢神经酰胺代谢谱数据与心血管病、2型糖尿病等的相关性进行分析。研究结果显示,多种神经酰胺化合物与心血管疾病和2型糖尿病风险有关。
关键字
延伸阅读本研究的原文信息和链接出处,以及相关解读和评论文章。欢迎读者朋友们推荐!
图片

Dihydroceramide- and ceramide-profiling provides insights into human cardiometabolic disease etiology

二氢神经酰胺和神经酰胺剖析为人类心血管代谢疾病病因提供洞见

10.1038/s41467-022-28496-1

02-17, Article

Abstract & Authors:展开

Abstract:收起
Metabolic alterations precede cardiometabolic disease onset. Here we present ceramide- and dihydroceramide-profiling data from a nested case-cohort (type 2 diabetes [T2D, n = 775]; cardiovascular disease [CVD, n = 551]; random subcohort [n = 1137]) in the prospective EPIC-Potsdam study. We apply the novel NetCoupler-algorithm to link a data-driven (dihydro)ceramide network to T2D and CVD risk. Controlling for confounding by other (dihydro)ceramides, ceramides C18:0 and C22:0 and dihydroceramides C20:0 and C22:2 are associated with higher and ceramide C20:0 and dihydroceramide C26:1 with lower T2D risk. Ceramide C16:0 and dihydroceramide C22:2 are associated with higher CVD risk. Genome-wide association studies and Mendelian randomization analyses support a role of ceramide C22:0 in T2D etiology. Our results also suggest that (dh)ceramides partly mediate the putative adverse effect of high red meat consumption and benefits of coffee consumption on T2D risk. Thus, (dihydro)ceramides may play a critical role in linking genetic predisposition and dietary habits to cardiometabolic disease risk.

First Authors:
C Wittenbecher

Correspondence Authors:
M B Schulze

All Authors:
C Wittenbecher,R Cuadrat,L Johnston,F Eichelmann,S Jäger,O Kuxhaus,M Prada,F Del Greco M,A A Hicks,P Hoffman,J Krumsiek,F B Hu,M B Schulze

评论